COVID-19 post-exposure prophylaxis
Showing 1 - 25 of >10,000
COVID-19 Trial (IBIO123, Placebo)
Not yet recruiting
- COVID-19
- IBIO123
- Placebo
- (no location specified)
Dec 5, 2022
COVID-19, SARS-CoV-2 Infection Trial in Beijing (HH-120 Nasal Spray)
Completed
- COVID-19
- SARS-CoV-2 Infection
- HH-120 Nasal Spray
-
Beijing, Beijing, ChinaBeijing Ditan Hospital,Capital Medical University
Feb 26, 2023
COVID-19, Viral Respiratory Illnesses Trial in United States (Nitazoxanide, Placebo, Vitamin Super B-Complex)
Terminated
- COVID-19
- Viral Respiratory Illnesses
- Nitazoxanide
- +2 more
-
Kissimmee, Florida
- +3 more
Jun 28, 2022
COVID-19, Corona Virus Infection, SARS (Severe Acute Respiratory Syndrome) Trial in United States (Hydroxychloroquine Sulfate,
Completed
- COVID-19
- +3 more
- Hydroxychloroquine Sulfate
- Ascorbic Acid
-
Los Angeles, California
- +7 more
Dec 14, 2021
COVID-19 Vaccination AZV 2021-2023
Recruiting
- COVID-19
- +3 more
- Vaccionation eighter started or full course
-
Hradec Kralove, CzechiaUniversity Hospital Hradec Kralove
Oct 21, 2022
COVID-19 Trial in Beijing, Shanghai (HH-120 Nasal Spray, Placebo)
Not yet recruiting
- COVID-19
- HH-120 Nasal Spray
- Placebo
-
Beijing, China
- +1 more
Mar 27, 2023
COVID-19, SARS-CoV 2 Trial in Sioux Falls (Hydroxychloroquine, Vitamin D)
Terminated
- COVID-19
- SARS-CoV 2
- Hydroxychloroquine
- Vitamin D
-
Sioux Falls, South DakotaSanford Health
Dec 8, 2021
Covid19 Trial in Tucumán (Ivermectin, Placebo)
Completed
- Covid19
- Ivermectin
- Placebo
-
Tucumán, ArgentinaSI.PRO.SA, Ministerio de Salud Pública
Dec 1, 2021
Contact Person From COVID-19 Confirmed Patient Trial in Seoul (Hydroxychloroquine as post exposure prophylaxis, Others(No
Withdrawn
- Contact Person From COVID-19 Confirmed Patient
- Hydroxychloroquine as post exposure prophylaxis
- Others(No intervention)
-
Seoul, Korea, Republic ofGangnam Severance Hospital
Aug 2, 2021
2019 Novel Coronavirus Disease, 2019 Novel Coronavirus Infection, 2019-nCoV Disease Trial in United States (Famotidine,
Terminated
- 2019 Novel Coronavirus Disease
- +11 more
- Famotidine
- +2 more
-
Newport Beach, California
- +14 more
Jul 20, 2022
SARS-CoV-2 Infection Trial in Beijing (HH-120 nasal spray 1, HH-120 nasal spray 2, Placebo Comparator 1)
Completed
- SARS-CoV-2 Infection
- HH-120 nasal spray 1
- +3 more
-
Beijing, Beijing, ChinaBeijing Ditan Hospital,Capital Medical University
Mar 1, 2023
Covid19, COVID-19 Prevention Trial in Chandigarh (Hydroxychloroquine (HCQ), Standard care, Placebo)
Recruiting
- Covid19
- COVID-19 Prevention
- Hydroxychloroquine (HCQ)
- +2 more
-
Chandigarh, IndiaPost Graduate Institute of Medical Education and Research
Jun 8, 2021
Covid19 Trial in Jaipur (Guduchi Ghanvati, Standard guidelines)
Completed
- Covid19
- Guduchi Ghanvati
- Standard guidelines
-
Jaipur, Rajasthan, India
- +1 more
Jun 9, 2021
Coronavirus Infections, Post-exposure Prophylaxis Trial in Vancouver, Toronto (Lopinavir/ritonavir)
Active, not recruiting
- Coronavirus Infections
- Post-exposure Prophylaxis
-
Vancouver, British Columbia, Canada
- +3 more
Nov 29, 2021
Covid19, SARS-CoV-2 Infection, Households Contacts Trial in Buenos Aires (Nitazoxanide, Placebo)
Recruiting
- Covid19
- +2 more
- Nitazoxanide
- Placebo
-
Buenos Aires, Ciudad Autonoma De Buenos Aires, ArgentinaFundación Huésped.
Jul 1, 2021
COVID-19 Trial in Manila (Hydroxychloroquine plus standard preventive measures, Placebo plus standard preventive measures)
Withdrawn
- COVID-19
- Hydroxychloroquine plus standard preventive measures
- Placebo plus standard preventive measures
-
Manila, PhilippinesPhilippine General Hospital - University of the Philippines Mani
Nov 4, 2020
COVID-19, SARS-CoV-2 Trial in Moscow, St Petersburg (Biological: AZD3152, Biological: Placebo)
Not yet recruiting
- COVID-19, SARS-CoV-2
- Biological: AZD3152
- Biological: Placebo
-
Moscow, Russian Federation
- +5 more
Sep 26, 2023
COVID-19 Trial in New York (Hydroxychloroquine (HCQ))
Completed
- COVID-19
- Hydroxychloroquine (HCQ)
-
New York, New YorkNYU Langone Health
Dec 12, 2022
SARS-CoV Infection, COVID-19 Trial (Mitoquinone/mitoquinol mesylate, Placebo)
Not yet recruiting
- SARS-CoV Infection
- COVID-19
- Mitoquinone/mitoquinol mesylate
- Placebo
- (no location specified)
Jun 1, 2023